Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer

Active, not recruitingOBSERVATIONAL

Enrollment

600

Participants

Timeline

Start Date

February 5, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

June 6, 2025

Conditions

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Trial Locations (1)

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Hunan Cancer Hospital

OTHER

NCT06748495 - Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter